Mesothelin-Expressing Tumors Clinical Trials
2 recruiting trials for Mesothelin-Expressing Tumors. Eligibility criteria explained in plain English.
TrialFinderData lists 2 Mesothelin-Expressing Tumors clinical trials drawn from ClinicalTrials.gov, all of which are currently recruiting participants.
Every phased trial in this set is Phase 1 (2 of the listed studies); the remaining records are observational or have no phase recorded on ClinicalTrials.gov.
Research is led by Memorial Sloan Kettering Cancer Center (1), Context Therapeutics Inc. (1), among the most active sponsors registered for these trials.
The most frequently studied intervention is M28z1XXPD1DNR CAR (biological, 1 trial), followed by CT-95.
Track Mesothelin-Expressing Tumors trials
Subscribe for TrialFinderData updates by email. No spam, unsubscribe anytime.
Recruiting Trials
Clinical trial data sourced from the ClinicalTrials.gov registry, maintained by the National Library of Medicine. Always consult your doctor before considering any clinical trial.
A Study of Mesothelin-Targeted CAR T-Cell Therapy in People With Esophagogastric Cancer
Participants will have a sample of their white blood cells, called T cells, collected using a procedure called leukapheresis. The collected T cells will be sent to a laboratory at...
CT-95 in Advanced Cancers Associated With Mesothelin Expression
This is a Phase 1a/1b, first-in-human (FIH), open-label, multi-center dose escalation and expansion study of the safety, pharmacokinetics (PK), pharmacodynamics, and antitumor...
Explore Other Conditions
Frequently Asked Questions
There are currently 2 clinical trials for Mesothelin-Expressing Tumors, with 2 actively recruiting participants. These include trials across all phases from early-stage Phase 1 to late-stage Phase 3.
To join a clinical trial for Mesothelin-Expressing Tumors, review the eligibility criteria on the trial detail pages, then talk to your doctor about whether a trial is right for you. Your doctor can help you evaluate the potential benefits and risks.
Phase 3 trials are large-scale studies that test whether a treatment is effective and monitor side effects. There are 0 Phase 3 trials for Mesothelin-Expressing Tumors, representing treatments closest to potential FDA approval.
Clinical trials follow strict safety protocols overseen by Institutional Review Boards (IRBs) and the FDA. Participants are monitored closely and can withdraw at any time. Always discuss risks and benefits with your healthcare provider before enrolling.
Trial data sourced from the ClinicalTrials.gov API. This site does not provide medical advice, always talk to your doctor about clinical trial participation.